在GLP-1肥胖药品的竞争和需求中, Elilly降低Zepbound价格, Eli Lilly lowered Zepbound prices to boost access, amid competition and demand for GLP-1 obesity drugs.

Eli Lilly已经降低了其肥胖药物的现金价格,在LillyDirect平台上,单剂量小瓶的肥胖药物为Zepbound, 最初剂量从每月349美元减少到299美元,5毫克剂量从499美元减少到399美元,较高的剂量为449美元。 Eli Lilly has cut the cash price of its obesity drug Zepbound for single-dose vials on its LillyDirect platform, reducing the starting dose to $299 per month from $349 and the 5 mg dose to $399 from $499, with higher doses at $449. 减少费用是Zepbund自费旅行方案的一部分,目的是改善未投保或未投保的病人获得服务的机会。 The reductions, part of the Zepbound Self Pay Journey Program, aim to improve access for uninsured or underinsured patients. 该公司还计划在林业发展局批准之前以较低的价格提供多剂量笔,并同意根据与特朗普政府的一项协议降低医疗保险、医疗补助和现金支付方案的价格。 The company also plans to offer multi-dose pens at lower prices pending FDA approval and has agreed to lower prices for Medicare, Medicaid, and cash-pay programs under a deal with the Trump administration. 这些行动是继对GLP-1药品的强劲需求以及竞争不断加剧之后采取的,诺沃·诺迪斯克也削减了价格。 These moves follow strong demand for GLP-1 drugs and rising competition, with Novo Nordisk also cutting prices.